Based on these data, NLRC5 has been validated to be a direct downstream target of miR-4319.2 In addition to the role of miR-4319 in tumor-suppression, miR-4319 inhibition could be a potential strategy to enhance NLRC5 expression, thereby promoting MHC class I expression, which is critical in cancer immunotherapy, including PD1/PD-L1 blockade. This evidence concerns the gene NLRC5 and neoplasm.